Skip to main content


All the latest news and information on the main advances in research, institutional milestones, teaching and management. Find out what happens at the Vall d'Hebron Research Institute!

The platform offers health workers the latest information on infectious and tropical diseases and also serves as a training tool.

This is a RACECAT secondary study published in JAMA Neurology that focuses on intracerebral haemorrhages.

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

The new drug improves core symptoms of depression in just three days

This new method improves and streamlines drug development processes

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Complemented with the analysis of genetic variants, the work led by Vall d'Hebron establishes the basis for using gene expression as a potential biomarker of risk of developing the disorder.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The results show that tobacco affects the expression of some genes related to the development of this type of headache.

The work improves accuracy in predicting complications at the boundary between the instrumented spine area and the area that is left free when spinal deformity corrective surgery is performed.

The Vall d’Hebron Research Institute (VHIR) makes its own and open call for a doctoral fellowship programme devoted to attracting early-stage researchers with a special interest in biomedical research who wish to carry out doctoral studies at VHIR

The IMM-CARE project has been presented at an institutional event in Lisbon.

The results of the study show for the first time that patients who start treatment less than six months after having the first symptoms of the disease have a slower progression and less disability than when therapy is started more than 16 months later.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.

It highlights the scientific and institutional results of the center during 2022.

Smartwatches are a practical, low-cost, noninvasive method that helps in the early detection of atrial fibrillations in some patients, which increase the risk of recurrent stroke.

The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

The research has received funding from the Spanish Society of Obesity Surgery and the Spanish Association of Surgeons.

Recently, a closing meeting was organised to wrap up the first phase of the study, which aims at grouping sufficient data of patient affected by these pathologies.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

This is the most prestigious international award in the multiple sclerosis scientific and social community, given in recognition of life-long work in care, research and teaching in relation to the disease.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.